Work

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.18_suppl.lba5

Authors: Roy S. Herbst, Masahiro Tsuboi, Thomas John, Christian Grohé, Margarita Majem, Jonathan Wade Goldman, Sang-We Kim, Dominika Marmol, Yuri Rukazenkov, Yi-Long Wu

Institutions: Yale Cancer Center, Yale University, National Cancer Center Hospital East, Austin Health, Evangelische Lungenklinik Berlin, Hospital de Sant Pau, University of California, Los Angeles, Asan Medical Center, AstraZeneca (United Kingdom), Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, South China University of Technology

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3033370892

Cites:

Cited by: 95

Related to: 10